A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival

Table 1 Clinical characteristics of the 412 DLBCL patients with data on RDI included in the AMARE cohort study and comparisons between RDI groups

		Total		RDI < 85% (n = 72)		RDI ≥ 85% (n = 340)		P value^a
		n	%	n	%	n	%	P value^a
Gender	Male	222	53.9	34	47.2	188	55.3	0.212
Gender	Female	190	46.1	38	52.8	152	44.7
Age	<59 y	146	35.4	14	19.4	132	38.8	<0.001
	59 - 73 y	135	32.8	20	27.8	115	33.8
	>73 y	131	31.8	38	52.8	93	27.4
Comorbidity	none	161	39.1	22	30.6	139	40.9	0.103
Comorbidity	at least 1	251	60.9	50	69.4	201	59.1
Standard International prognostic index (sIPI)	very good	56	13.6	5	6.9	51	15	<0.001
	good	217	52.7	29	40.3	188	55.3
	poor	122	29.6	37	51.4	85	25
	missing	17	4.1	1	1.4	16	4.7
LDH	normal	197	47.8	27	37.5	170	50	0.054
LDH	elevated	215	52.2	45	62.5	170	50
B signs	absence	336	81.6	61	84.7	275	80.9	0.445
B signs	presence	76	18.5	11	15.3	65	19.1
Ann Arbor Stage	I-II	142	34.5	15	20.8	127	37.4	0.007
Ann Arbor Stage	III-IV	270	65.5	57	79.2	213	62.7
Performance status	PS = 0-1	385	93.5	69	95.8	316	92.9	0.598 ^b
Performance status	PS = 2-4	27	6.6	3	4.2	24	7.1
Regimens	R- CHOP 21 or R-CHVP	223	54.1	28	38.9	195	57.4	<0.001 ^b
	R- CHOP 14	34	8.3	10	13.9	24	7.1
	R- ACVBP	45	10.9	3	4.2	42	12.4
	R-mini CHOP or R-mini CHVP	100	24.3	30	41.7	70	20.6
	other	10	2.4	1	1.4	9	2.7

In bivariate analyses, p-values derived from the chi2 test ^a or the Fisher Exact test ^b when the expected frequencies were less than 5.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; LDH: lactate dehydrogenase.

ISSN: 1471-2407